SC 13G/A | 2014-02-14 | SAC Capital Advisors LP | INTERCEPT PHARMACEUTICALS INC | 1,369,046 | 7.1% | EDGAR |
SC 13G/A | 2014-02-13 | Genextra S.p.A. | INTERCEPT PHARMACEUTICALS INC | 6,804,271 | 33.7% | EDGAR |
SC 13G | 2014-01-10 | Visium Asset Management, LP | INTERCEPT PHARMACEUTICALS INC | 1,000,426 | 5.2% | EDGAR |
SC 13G | 2013-11-08 | SAC Capital Advisors LP | INTERCEPT PHARMACEUTICALS INC | 988,097 | 5.1% | EDGAR |
SC 13D/A | 2013-10-18 | ORBIMED ADVISORS LLC | INTERCEPT PHARMACEUTICALS INC | 1,775,672 | 9.2% | EDGAR |
SC 13G/A | 2013-07-10 | FMR LLC | INTERCEPT PHARMACEUTICALS INC | 1,999,469 | 10.7% | EDGAR |
SC 13D | 2013-04-17 | Pruzanski Mark | INTERCEPT PHARMACEUTICALS INC | 871,087 | 5.1% | EDGAR |
SC 13G | 2013-02-14 | FMR LLC | INTERCEPT PHARMACEUTICALS INC | 1,124,008 | 6.8% | EDGAR |
SC 13G | 2013-02-14 | Genextra S.p.A. | INTERCEPT PHARMACEUTICALS INC | 8,052,598 | 46.4% | EDGAR |
SC 13D | 2012-10-26 | ORBIMED ADVISORS LLC | INTERCEPT PHARMACEUTICALS INC | 2,150,634 | 13.7% | EDGAR |